The Italian Medicines Agency has given the green light to the reimbursement of trastuzumab deruxtecan, the monoclonal antibody drug-conjugate from Daiichi Sankyo and AstraZeneca, for the treatment of patients with metastatic breast cancer and low expression of the HER2 protein (HER2 low) . The new therapeutic option substantially improves both progression-free survival and overall survival.
#Her2 #metastatic #breast #cancer #therapy #AstraZeneca #Daiichi #Sankyo
